Menu Search
Equities

Lineage Cell Therapeutics Inc

BT3:BER

Lineage Cell Therapeutics Inc

Actions
  • Price (EUR)0.56
  • Today's Change-0.06 / -9.68%
  • Shares traded--
  • 1 Year change-34.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Lineage Cell Therapeutics Inc had revenues fall -39.16% from 14.70m to 8.95m, though the company grew net income from a loss of 26.27m to a smaller loss of 21.49m.
Gross margin95.00%
Net profit margin-229.91%
Operating margin-260.70%
Return on assets-19.77%
Return on equity-29.95%
Return on investment-22.80%
More ▼

Cash flow in USDView more

In 2023, Lineage Cell Therapeutics Inc increased its cash reserves by 201.54%, or 24.06m. Cash Flow from Investing totalled 46.45m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 28.57m for operations while cash generated from financing totalled 6.42m.
Cash flow per share-0.1056
Price/Cash flow per share--
Book value per share0.3505
Tangible book value per share0.0475
More ▼

Balance sheet in USDView more

Lineage Cell Therapeutics Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.21%.
Current ratio2.48
Quick ratio--
Total debt/total equity0.002
Total debt/total capital0.0021
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.